iCAD, Inc. (ICAD)
- Previous Close
1.5600 - Open
1.5900 - Bid 1.5400 x 100
- Ask 1.6200 x 100
- Day's Range
1.4750 - 1.6000 - 52 Week Range
1.0500 - 3.9700 - Volume
143,053 - Avg. Volume
210,291 - Market Cap (intraday)
41.903M - Beta (5Y Monthly) 1.35
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2700 - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.83
iCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.
www.icadmed.comRecent News: ICAD
Performance Overview: ICAD
Trailing total returns as of 4/18/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ICAD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ICAD
Valuation Measures
Market Cap
41.90M
Enterprise Value
20.69M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.35
Price/Book (mrq)
1.25
Enterprise Value/Revenue
1.19
Enterprise Value/EBITDA
-3.15
Financial Highlights
Profitability and Income Statement
Profit Margin
-27.99%
Return on Assets (ttm)
-10.32%
Return on Equity (ttm)
-20.52%
Revenue (ttm)
17.32M
Net Income Avi to Common (ttm)
-7.01M
Diluted EPS (ttm)
-0.2700
Balance Sheet and Cash Flow
Total Cash (mrq)
21.67M
Total Debt/Equity (mrq)
1.38%
Levered Free Cash Flow (ttm)
-2.11M
Research Analysis: ICAD
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell